Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced a research collaboration with Atossa Therapeutics. The collaboration leverages Nona’s proprietary H2L2 Harbour Mice® platform to identify next-generation therapeutic candidates for breast cancer.
Nona Biosciences’ proprietary Harbour Mice® platform employs transgenic mice to generate fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization. Combined with the single B cell cloning technology, this platform offers a powerful approach to developing therapeutic antibodies and accelerating drug discovery and development. To date, Harbour Mice® platform has been applied in more than 250 drug discovery programs across multiple therapeutic areas and has been widely recognized by global partners.
Also Read: PharmaLogic to Acquire Majority Stake in Agilera, Strengthening Global Expertise in Radiopharmaceutical Therapeutics
“We are pleased to collaborate with Atossa Therapeutics to discover next-generation antibody therapies for breast cancer,” said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences. “This partnership highlights the value of our proprietary Harbour Mice® platform and reflects the industry’s growing demand for innovative antibody discovery solutions. With Nona’s industry-leading technology and expertise, we look forward to supporting Atossa’s exploration of antibody-based approaches within their oncology pipeline.”
SOURCE: PRNewswire